SCHEMBL259017

SCHEMBL259017

COC(=O)N(CCOCCOCC(=O)O)C1c2ccccc2-c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MEN1 O00255 1/20 0.35
ADRB2 P07550 1/20 0.35
ADRB1 P08588 1/20 0.35
CYP2D6 P10635 1/20 0.35
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
SLC22A2 O15244 1/20 0.34
SLC22A3 O75751 1/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
GPR3 P46089 1/20 0.33
PTGIR P43119 3/20 0.33
PTGDR Q13258 2/20 0.33
KDM4E B2RXH2 1/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4557180 1.00 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL4557245 1.00 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL1593611 1.00 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL4557017 1.00 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL1594270 0.93 ALDH1A1 (0.40) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL23327864 0.92 SMN1; SMN2 (0.36) ALDH1A1KMT2ASMN1; SMN2MEN1CA1
SCHEMBL17211371 0.90 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL2173884 0.90 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL20767261 0.90 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2
SCHEMBL17435149 0.90 ALDH1A1 (0.39) ALDH1A1KMT2ASMN1; SMN2MEN1ADRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559529-B2 NPY2 receptor agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2026-02-24 US disclosed
US-20260015399-A1 SOLUBLE NPY2 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INT (DE) 2026-01-15 US disclosed
US-20260014257-A1 THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 CYTOKI PHARMA APS (DK) 2026-01-15 US disclosed
US-20250360186-A1 DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES CYTOKI PHARMA APS (DK) 2025-11-27 US disclosed
EP-3448417-B1 INSULIN DIMER-INCRETIN CONJUGATES MERCK SHARP & DOHME LLC (US) 2025-11-12 EP disclosed
US-12447211-B2 Therapeutic derivatives of interleukin-22 CYTOKI PHARMA APS (DK) 2025-10-21 US disclosed
US-20250282824-A1 Inhibitors of the Wnt Signaling Pathway and Uses Thereof STICHTING VU (NL) 2025-09-11 US disclosed
US-20250269046-A1 CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES FORSCHUNGSVERBUND BERLIN E.V. (DE) 2025-08-28 US disclosed
US-20250270253-A1 SITE-SELECTIVE MODIFICATION OF PROTEINS UNIVERSITY OF COPENHAGEN (DK) 2025-08-28 US disclosed
EP-3740229-B1 INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN HAVING A PI OF BETWEEN 5.8 AND 8.5 AND A COPOLYAMINO ACID CARRYING CARBOXYLATE CHARGES AND HYDROPHOBIC RADICALS ADOCIA (FR) 2025-04-09 EP disclosed
EP-2183273-A1 CYCLIC DEPSIPEPTIDES Novartis Ag (CH) 2010-05-12 EP disclosed
WO-2010029159-A1 METHOD OF ACYLATING A PEPTIDE OR PROTEIN NOVO NORDISK A/S (DK) 2010-03-18 WO disclosed
US-20090312197-A1 PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME PANAGENE INC. (KR) 2009-12-17 US disclosed
US-20090156472-A1 Cyclic Depsipeptides NOVARTIS AG (CH) 2009-06-18 US disclosed
US-20090111730-A1 Polypeptide protracting tags NOVO NORDISK A/S (DK) 2009-04-30 US disclosed
WO-2009024527-A1 CYCLIC DEPSIPEPTIDES NOVARTIS AG (CH) 2009-02-26 WO disclosed
US-20080248461-A1 PNA Probes, Kits, and Methods for Detecting Genotypes of Human Papillomavirus PANAGENE INC. (KR) 2008-10-09 US disclosed
US-20080233557-A1 PNA Probes, Kits, and Methods for Detecting Lamivudine-Resistant Hepatitis B Viruses PANAGENE INC. (KR) 2008-09-25 US disclosed
EP-1765408-A2 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK A/S (DK) 2007-03-28 EP disclosed
WO-2006005667-A2 POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY NOVO NORDISK A/S (DK) 2006-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312197-A1 PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME NPPA, PARN, PARG ALDH1A1 3477/4885KMT2A 548/4885SMN1; SMN2 3036/4885
US-20080233557-A1 PNA Probes, Kits, and Methods for Detecting Lamivudine-Resistant Hepatitis B Viruses POLM, RNPEP, PNP ALDH1A1 4268/4885KMT2A 3566/4885SMN1; SMN2 4734/4885
US-20250282824-A1 Inhibitors of the Wnt Signaling Pathway and Uses Thereof WNT1, WNT3, WNT3A ALDH1A1 4537/4885KMT2A 2588/4885SMN1; SMN2 3845/4885
US-20080248461-A1 PNA Probes, Kits, and Methods for Detecting Genotypes of Human Papillomavirus POLI, PAIP1, PRAP1 ALDH1A1 3802/4885KMT2A 3133/4885SMN1; SMN2 4389/4885
US-20250269046-A1 CELLULAR UPTAKE OF LARGE BIOMOLECULES ENABLED BY CELL-SURFACE-REACTIVE CELL-PENETRATING PEPTIDE ADDITIVES GZMB, SLC7A5, SLC7A1 ALDH1A1 3376/4885KMT2A 4012/4885SMN1; SMN2 3110/4885
US-12447211-B2 Therapeutic derivatives of interleukin-22 IL2, IL2RA, IL23R ALDH1A1 860/4885KMT2A 1666/4885SMN1; SMN2 3121/4885
US-20250270253-A1 SITE-SELECTIVE MODIFICATION OF PROTEINS PTMS, DNPEP, AADAC ALDH1A1 4292/4885KMT2A 252/4885SMN1; SMN2 4844/4885
US-20250360186-A1 DOSAGE REGIMEN FOR INTERLEUKIN-22 DERIVATIVES IL2, FABP2, IL2RA ALDH1A1 483/4885KMT2A 1972/4885SMN1; SMN2 4031/4885
US-20090156472-A1 Cyclic Depsipeptides SERPINB1, ELANE, KLK7 ALDH1A1 3924/4885KMT2A 3094/4885SMN1; SMN2 3808/4885
US-20090111730-A1 Polypeptide protracting tags LNPEP, FGB, ENPEP ALDH1A1 3105/4885KMT2A 4689/4885SMN1; SMN2 1647/4885
US-20260015399-A1 SOLUBLE NPY2 RECEPTOR AGONISTS NPY1R, NPY2R, NPY5R ALDH1A1 4878/4885KMT2A 2872/4885SMN1; SMN2 2607/4885
US-12559529-B2 NPY2 receptor agonists NPY2R, NPY5R, NPY1R ALDH1A1 4624/4885KMT2A 679/4885SMN1; SMN2 1470/4885
US-20260014257-A1 THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 IL2, IL23R, IL36G ALDH1A1 2432/4885KMT2A 1926/4885SMN1; SMN2 3876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.